Topics

Questcor Pharmaceuticals Incorporated
Mallinckrodt buying Questcor for about $5.2 billion

ANAHEIM — Mallinckrodt is buying Anaheim-based Questcor Pharmaceuticals Inc. for a combination of stock and cash valued at about $5.2 billion. Mallinckrodt makes a range of specialty pharmaceuticals. Questcor's primary product is H.P. Acthar Gel, which is used in the management of autoimmune and inflammatory conditions. It is approved in the U.S. for treating 19 indications. "The increased cash flow and scale of operations of a combined Questcor/Mallinckrodt organization will provide an even stronger platform to support the expansion of Acthar into new therapeutic areas," Questcor President and CEO Don Bailey said in a statement. Questcor stockholders will...

Loading